Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taminadenant +/- Spartalizumab in Advanced NSCLC
NCT02403193Phase 1Completed
- Sponsor
- Palobiofarma
- Start
- Oct 2015
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taminadenant in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Palobiofarma. Primary endpoints: Maximum Tolerated Dose of PBF-509 as single agent at 28 days and Maximum Tolerated Dose of PBF-509 + PDR001 at 56 days. Started Oct 2015; status: completed.
02
Drugs
taminadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02403193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403193.